uniQure N.V. (QURE)
NASDAQ: QURE · Real-Time Price · USD
16.98
+1.51 (9.76%)
At close: Dec 20, 2024, 4:00 PM
16.85
-0.13 (-0.77%)
After-hours: Dec 20, 2024, 7:45 PM EST
uniQure Employees
uniQure had 480 employees as of December 31, 2023. The number of employees decreased by 21 or -4.19% compared to the previous year.
Employees
480
Change (1Y)
-21
Growth (1Y)
-4.19%
Revenue / Employee
$59,556
Profits / Employee
-$498,960
Market Cap
827.66M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Avanos Medical | 3,771 |
agilon health | 1,117 |
Cytek Biosciences | 676 |
Castle Biosciences | 610 |
Standard BioTools | 539 |
Cronos Group | 356 |
Tyra Biosciences | 49 |
Oculis Holding AG | 36 |
QURE News
- 11 days ago - uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease - GlobeNewsWire
- 4 weeks ago - uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy - GlobeNewsWire
- 6 weeks ago - uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewsWire
- 2 months ago - uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS - GlobeNewsWire
- 3 months ago - uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire
- 4 months ago - uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - GlobeNewsWire
- 4 months ago - uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity - Seeking Alpha
- 5 months ago - uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update - GlobeNewsWire